All In Biotech

Free tool

FAERS Monitor: Myqorzo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219083 or its brand name (Myqorzo, Aficamten). Reports on generic versions are filed under their own applications.

Reports

497

Serious

159

32% of reports

Hospitalization

99

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea58
  • fatigue45
  • dizziness44
  • product dose omission issue44
  • blood pressure increased33
  • chest pain33
  • headache26
  • product use issue22
  • atrial fibrillation17
  • peripheral swelling17
  • drug ineffective16
  • asthenia15
  • palpitations15
  • cardiac failure14
  • malaise14

Reports by year received

View as table
YearReports
2026497

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,662 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood pressure increasedSignal339.16.6233
chest painSignal337.55.4182
atrial fibrillationSignal177.44.688
cardiac failureSignal147.44.471
product dose omission issueSignal446.34.8195
palpitationsSignal155.43.350
product use issueSignal225.03.366
peripheral swellingSignal174.72.946
dyspnoeaSignal584.33.4150
dizzinessSignal443.72.887
fatigueSignal452.41.938
headache261.81.28
asthenia151.71.04
malaise141.40.81
drug ineffective160.50.37

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.